ChAdOx1 nCoV-19 clinical trials
Also written AZD1222, Covishield and Vaxzevria.
How each study uses ChAdOx1 nCoV-19 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2021 (16)
| Year | Studies |
|---|---|
| 2020 | 6 |
| 2021 | 16 |
| 2022 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 16
AstraZeneca (5) · University of Oxford (4) · R-Pharm (3) · Medigen Vaccine Biologics Corp. (2) · Federal University of Espirito Santo (2) · Jens D Lundgren, MD (1) · Albert B. Sabin Vaccine Institute (1) · Universiteit Antwerpen (1)
Often tested with
Tested in the same studies.
BNT162 Vaccine (5) · R-AD26-S (recombinant adenovirus type 26 carrying THE gene FOR severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike glycoprotein) (3) · 2019-nCoV Vaccine mRNA-1273 (2) · MenACWY (1) · Acetaminophen (1) · ChAdOx1-vectored COVID-19 Variant Vaccine AZD2816 (1) · Sinovac COVID-19 vaccine (1) · BBV152 COVID-19 vaccine (1)
Studies
Open first, then newest update. How each study uses ChAdOx1 nCoV-19 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- Investigating a Vaccine Against COVID-19CompletedPhase 2/3University of OxfordNCT04400838Written as ChAdOx1 nCoV-19 (Abs 260)How we know
- A Study of a Candidate COVID-19 Vaccine (COV001)CompletedPhase 1/2University of OxfordNCT04324606Written as ChAdOx1 nCoV-19How we know
- A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised AdultsTerminatedPhase 4AstraZenecaNCT05057897Written as AZD1222How we know
- Phase II/III Study of AZD2816, for the Prevention of COVID-19 in AdultsCompletedPhase 2/3AstraZenecaNCT04973449Written as AZD1222How we know
- National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)CompletedPhase 4Jens D Lundgren, MDNCT04760132Written as COVID-19 Vaccine AstraZeneca suspension for injectionHow we know
- Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)WithdrawnPhase 3Murdoch Childrens Research InstituteNCT05387317Written as AstraZeneca Standard doseHow we know
- Study of AZD1222 for the Prevention of COVID-19 in JapanCompletedPhase 1/2AstraZenecaNCT04568031Written as AZD1222How we know
- Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsCompletedPhase 3AstraZenecaNCT04516746Written as AZD1222How we know
- Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing TrialCompletedPhase 4Albert B. Sabin Vaccine InstituteNCT05343871Written as AZD1222How we know
- Immunogenicity After COVID-19 Vaccines in Adapted SchedulesCompletedPhase 4Universiteit AntwerpenNCT06189040Written as ChAdOx1-S [Recombinant]How we know
- Antibody Response to COVID-19 Vaccines in Liver Disease PatientsCompletedPhase 4Humanity & Health Medical Group LimitedNCT04775069Written as AZD1222How we know
- Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and DeathCompletedPhase 4Shabir MadhiNCT04914832Written as AZD1222How we know
- A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19CompletedPhase 2Medigen Vaccine Biologics Corp.NCT05197153Written as AZD1222How we know
- Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2CompletedPhase 3Botswana Harvard AIDS Institute PartnershipNCT05715944Written as AZD 1222How we know
- Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)CompletedPhase 1/2R-PharmNCT04760730Written as AZD1222How we know
- A Study of Intranasal ChAdOx1 nCOV-19CompletedPhase 1University of OxfordNCT04816019Written as ChAdOx1 nCov-19How we know
- Efficacy and Safety of Heterologous and Homologous COVID-19 VaccinationCompletedNot applicableNational Taiwan University HospitalNCT05074368Written as ChAdOx1-nCov-19 (Astra-Zeneca)How we know
- Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster DoseCompletedPhase 3Bharat Biotech International LimitedNCT05567471Written as CovishieldHow we know
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in AdultsCompletedPhase 3Medigen Vaccine Biologics Corp.NCT05011526Written as AZD1222How we know
- Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCompletedPhase 2R-PharmNCT04686773Written as AZD1222How we know
See all 27 studies that test ChAdOx1 nCoV-19 →
As the comparator · 9 — what is tested is compared with ChAdOx1 nCoV-19
- Mix and Match of the COVID-19 Vaccine for Safety and ImmunogenicityCompletedPhase 2Canadian Immunization Research NetworkNCT04894435Written as ChAdOx1-S [recombinant]How we know
- The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)CompletedPhase 2/3Vinbiocare Biotechnology Joint Stock CompanyNCT05012943Written as Astra Zeneca COVID-19 vaccineHow we know
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.CompletedPhase 2/3Laboratorio Avi-Mex, S.A. de C.V.NCT05710783Written as ChAdOx-1-S[recombinant]How we know
- A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and OlderCompletedPhase 3EuBiologics Co.,LtdNCT05603052Written as ChAdOx1 nCoV-19How we know
- A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy AdultsCompletedPhase 3EuBiologics Co.,LtdNCT05572879Written as ChAdOx1 nCoV-19How we know
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and AboveCompletedPhase 3Medigen Vaccine Biologics Corp.NCT05198596Written as AZD1222How we know
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222CompletedPhase 3Medigen Vaccine Biologics Corp.NCT05426343Written as AZD1222How we know
- COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222CompletedPhase 3Valneva Austria GmbHNCT04864561Written as AZD1222How we know
- Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and OlderStatus unknownPhase 3Everest Medicines (Singapore) Pte. Ltd.NCT05534035Written as Vaxzevria®How we know
Codes
What other systems call ChAdOx1 nCoV-19 · ClinicalTrials.gg INT006860
- MeSH (NLM) D000090985ChAdOx1 nCoV-19One source NLM
- UNII (FDA) B5S3K2V0G8AZD-1222Confirmed FDA, NLM
- NCI Thesaurus C173021ChAdOx1 nCoV-19 VaccineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000090985 | ChAdOx1 nCoV-19 | One source NLM |
| UNII (FDA) | B5S3K2V0G8 | AZD-1222 | Confirmed FDA, NLM |
| NCI Thesaurus | C173021 | ChAdOx1 nCoV-19 Vaccine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.